Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5324, USA.
Thromb Haemost. 2010 Jul;104(1):13-22. doi: 10.1160/TH09-08-0530. Epub 2010 May 10.
The high mortality rate associated with cardiovascular disease is partially due to the lack of proliferative cells in the heart. Without adequate repair following myocardial infarction, progressive dilation can lead to heart failure. Stem cell therapies present one promising option for treating cardiovascular disease, though the specific mechanisms by which they benefit the heart remain unclear. Before stem cell therapies can be used safely in human populations, their biology must be investigated using innovative technologies such as multi-modality molecular imaging. The present review will discuss the basic principles, labelling techniques, clinical applications, and drawbacks associated with four major modalities: radionuclide imaging, magnetic resonance imaging, bioluminescence imaging, and fluorescence imaging.
心血管疾病死亡率高,部分原因是心脏中缺乏增殖细胞。心肌梗死后如果没有适当的修复,心脏会逐渐扩张,导致心力衰竭。干细胞疗法为治疗心血管疾病提供了一个有前途的选择,尽管它们对心脏有益的确切机制尚不清楚。在将干细胞疗法安全地应用于人类之前,必须使用多模态分子成像等创新技术对其生物学特性进行研究。本文综述了四种主要模式的基本原理、标记技术、临床应用和缺点:放射性核素成像、磁共振成像、生物发光成像和荧光成像。
Thromb Haemost. 2010-5-10
Expert Rev Cardiovasc Ther. 2010-8
J Cardiovasc Magn Reson. 2014-1-10
J Nucl Cardiol. 2006-7
Prog Cardiovasc Dis. 2007
Eur J Nucl Med Mol Imaging. 2005-12
J Cardiovasc Transl Res. 2011-5-3
Methodist Debakey Cardiovasc J. 2012-1
J Cardiothorac Vasc Anesth. 2019-1
Radiology. 2007-8
Circ Cardiovasc Imaging. 2018-2
Stem Cells Int. 2016
J Cardiovasc Magn Reson. 2014-1-10
Curr Vasc Pharmacol. 2012-5
Cell Cycle. 2009-8-15
Thromb Haemost. 2009-4
J Nucl Med. 2009-2
Biochem Biophys Res Commun. 2009-2-20
Rev Cardiovasc Med. 2008
Nat Clin Pract Oncol. 2009-1